Key Clinical Takeaways Study Design & Population: This rigorously conducted, double-blind, randomised controlled trial enrolled 17,604 patients across 41 countries
Research involves microencapsulating potent bitter compounds that remain tasteless in the mouth but bloom or activate once they reach the stomach and intestines, triggering the GLP-1 response without compromising the foods flavor profile
Like Comment Transcript Breaking news and it's not good news
Some of the evaluated GLP-1 RAs were associated with a significant increased risk of constipation, in the following order: semaglutide (RR 2.0979 [95% CI 1.6722, 2.6321
This makes the total treatment duration shorter and more cost-effective
If something else is more likely to get you where you want to go, well tell you that too